Plain-English translation of NCT07367815 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether CellREADY®—a new treatment made from stem cells derived from donated fat tissue—is safe and tolerable when injected into the bloodstream of people with mild to moderate Alzheimer's disease. The stem cells are believed to work by reducing inflammation and stimulating the brain's natural repair processes. The study will start with a small dose in a few patients, then gradually increase to higher doses if safety looks good.
Most treatments for Alzheimer's today only temporarily slow symptoms, but don't address the underlying brain changes. This medication may work differently by calming inflammation and encouraging the brain to repair and regenerate itself—offering a potentially new way to help people in the early stages of the disease.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion (injection into your vein) of the stem cell treatment at the hospital. The study begins with a small group of 3 patients receiving the lowest dose; if that is safe after 6 months of follow-up, the next group of 3 patients will receive a higher dose. You will have multiple visits over several months for safety checks, brain imaging (MRI and PET scans), memory and thinking tests, and blood work to monitor how the treatment affects you.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
France